These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 21078010)

  • 61. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
    Atkinson SD; Prakash A; Zhang Q; Pangallo BA; Bangs ME; Emslie GJ; March JS
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):180-9. PubMed ID: 24813026
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.
    Emslie GJ; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):170-9. PubMed ID: 24815533
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds.
    Fornaro M; Rocchi G; Escelsior A; Contini P; Martino M
    J Affect Disord; 2013 Mar; 145(3):300-7. PubMed ID: 22981313
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
    Thase ME; Pritchett YL; Ossanna MJ; Swindle RW; Xu J; Detke MJ
    J Clin Psychopharmacol; 2007 Dec; 27(6):672-6. PubMed ID: 18004135
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.
    Sheffrin M; Driscoll HC; Lenze EJ; Mulsant BH; Pollock BG; Miller MD; Butters MA; Dew MA; Reynolds CF
    J Clin Psychiatry; 2009 Feb; 70(2):208-13. PubMed ID: 19210951
    [TBL] [Abstract][Full Text] [Related]  

  • 67. An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.
    Lewis-Fernández R; Lam P; Lucak S; Galfalvy H; Jackson E; Fried J; Rosario M; de la Cruz AA; Sánchez-Lacay A; Díaz S; Schneier F
    J Clin Psychopharmacol; 2016 Dec; 36(6):710-715. PubMed ID: 27755218
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol.
    Oakes TM; Myers AL; Marangell LB; Ahl J; Prakash A; Thase ME; Kornstein SG
    Hum Psychopharmacol; 2012 Jan; 27(1):47-56. PubMed ID: 22241678
    [TBL] [Abstract][Full Text] [Related]  

  • 69. An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group.
    Berk M; du Plessis AD; Birkett M; Richardt D
    Int Clin Psychopharmacol; 1997 May; 12(3):137-40. PubMed ID: 9248869
    [TBL] [Abstract][Full Text] [Related]  

  • 70. VEGF plasma level variations in duloxetine-treated patients with major depression.
    Fornaro M; Rocchi G; Escelsior A; Contini P; Ghio M; Colicchio S; De Berardis D; Amore M; Fornaro P; Martino M
    J Affect Disord; 2013 Nov; 151(2):590-595. PubMed ID: 23871390
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.
    Raskin J; Wiltse CG; Siegal A; Sheikh J; Xu J; Dinkel JJ; Rotz BT; Mohs RC
    Am J Psychiatry; 2007 Jun; 164(6):900-9. PubMed ID: 17541049
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder.
    Montejo AL; Perahia DG; Spann ME; Wang F; Walker DJ; Yang CR; Detke MJ
    J Sex Med; 2011 Mar; 8(3):773-82. PubMed ID: 21091877
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
    Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
    BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder.
    Delgado PL; Brannan SK; Mallinckrodt CH; Tran PV; McNamara RK; Wang F; Watkin JG; Detke MJ
    J Clin Psychiatry; 2005 Jun; 66(6):686-92. PubMed ID: 15960560
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder.
    Perlis RH; Fijal B; Adams DH; Sutton VK; Trivedi MH; Houston JP
    Biol Psychiatry; 2009 May; 65(9):785-91. PubMed ID: 19095219
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
    Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Electroretinographic assessment in major depressed patients receiving duloxetine: might differences between responders and non-responders indicate a differential biological background?
    Fornaro M; Bandini F; Ogliastro C; Cordano C; Martino M; Cestari L; Escelsior A; Rocchi G; Colicchio S; Perugi G
    J Affect Disord; 2011 Dec; 135(1-3):154-9. PubMed ID: 21820182
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder.
    Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Guzmán D; Guàrdia-Olmos J; Hinojosa-Calvo E; Herrera-Abarca JE
    J Psychiatr Res; 2009 Jun; 43(9):855-63. PubMed ID: 19128810
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
    Lam RW; Lönn SL; Despiégel N
    Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Duloxetine: a review of its use in the treatment of major depressive disorder.
    Frampton JE; Plosker GL
    CNS Drugs; 2007; 21(7):581-609. PubMed ID: 17579500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.